You are here

  • Home
  • Archive
  • Volume 73, Issue 1
  • Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)

Citation Tools

Article menu
XML
Clinical and epidemiological research
Extended report
Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Mease PJ, Fleischmann R, Deodhar AA, et al
Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)
Annals of the Rheumatic Diseases 2014;73:48-55.